GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: CRL
Neutral

Charles River Laboratories International, Inc. (NYSE: CRL) upgraded to Neutral by Citigroup

Tuesday,  Feb 18, 2014  8:25 AM ET by Kristen Bailey

Citigroup upgraded Charles River Laboratories International, Inc. (NYSE: CRL) to
Neutral. Citigroup rated Charles River Laboratories International, Inc. (NYSE: CRL) to Sell on 04/03/2013, when the price was $41.67.

Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company provides the animal research models required in research and development of drugs, devices and therapies. Charles River?s customer base includes global pharmaceutical companies, a range of biotechnology companies, as well as government agencies, hospitals and academic institutions worldwide. The Company operates approximately 70 facilities in 17 countries worldwide. During the fiscal year ended December 27, 2008 (fiscal 2008), the Company acquired NewLab BioQuality AG and MIR Preclinical Services.

Citi Investment Research is a highly respected research unit and is comprised of 390 research analysts across 22 countries. Citi Investment Research covers 3,100 companies, representing 90 percent of the market capitalization of the major global indices, and provides macro and quantitative analysis of global markets and sector trends. Combined with Citi's exceptional sales and trading capabilities and Smith Barney's financial consultants, the core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy